71691 - Long-term overall survival after isolated liver perfusion with melphalan in patients with isolated liver metastases of uveal melanoma (SCANDIUM trial)

Le résumé fourni par la source

Abstract Introduction Uveal melanoma, a rare subtype of melanoma, often spreads to the liver, resulting in poor prognosis with limited treatment options. The SCANDIUM trial investigated the efficacy of isolated hepatic perfusion (IHP) with high-dose melphalan compared to investigators choice of treatment for patients with liver metastases from uveal melanoma. We have previously reported superior response rates and progression-free survival with IHP, although overall survival (OS) at 24 months did not reach statistical significance. Here we present extended OS follow-up data. Method In this phase III trial, treatment-naïve nordic patients with isolated liver metastases from uveal melanoma were randomized between 2013 and 2021 to receive either IHP or best alternative care in a 1:1 ratio, with no crossover allowed. All IHP treatments were performed at Sahlgrenska University hospital. Result Patients were randomized to IHP (n=43) or control (n=44). In the IHP group, 89% underwent the procedure. The control group received chemotherapy (49%), immunotherapy (39%) or localized treatment interventions (9%). The overall response rate in the IHP group was 40%, with a median response duration of 13.7 months. At a minimum 36-month follow-up, the 3-year OS rate was 18.6% in the IHP group compared to 9.1% in the control group (p=0.23). The 5-year OS rate was 16.3% versus 6.8%, respectively. Median OS was 21.4 months in the IHP group and 17.3 months in the control group (p=0.11, log-rank test). Discussion Extended analysis of the SCANDIUM trial confirms the long-term efficacy of one-time IHP treatment compared to best alternative care for isolated liver metastases from uveal melanoma.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.